Search Results
Showing 5 of 5 search results for:
Study of bb2121 in Multiple Myeloma
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: bb2121
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 1 of 5
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: bb2121, Drug: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone, Drug: Bortezomib, Drug: Ixazomib, Drug: Lenalidomide, Drug: Carfilzomib, Drug: Elotuzumab
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 2 of 5
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: bb2121 carfilzomib, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Lenalidomide
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 3 of 5
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: bb2121
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 4 of 5
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Status
Condition
Multiple Myeloma
Phase
INTERVENTION
Biological: bb2121
Eligibility
Ages Eligible for Study :
Sexes Eligible for Study : All
Accepts Healthy Volunteers :
Result 5 of 5